Retrospective Analysis of the Safety and Efficacy of High-dose Interleukin-2 After Prior Tyrosine Kinase Inhibitor Therapy in Patients With Advanced Renal Cell Carcinoma

Although tyrosine kinase inhibitors (TKI) are the most common first-line therapy for metastatic renal cell carcinoma, high-dose interleukin-2 (HD-IL2) remains the only agent that provides durable complete responses. The optimal sequence of these agents remains uncertain. This retrospective multi-ins...

Descripción completa

Detalles Bibliográficos
Autores principales: Lam, Elaine T., Wong, Michael K. K., Agarwal, Neeraj, Redman, Bruce G., Logan, Theodore, Gao, Dexiang, Flaig, Thomas W., Lewis, Karl, Poust, Jamie, Monk, Paul, Jarkowski, Anthony, Sendilnathan, Arun, Bolden, Marcus, Kuzel, Timothy M., Olencki, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2014
Materias:
Clinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127096/
https://www.ncbi.nlm.nih.gov/pubmed/25075565
http://dx.doi.org/10.1097/CJI.0000000000000044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127096/
https://www.ncbi.nlm.nih.gov/pubmed/25075565
http://dx.doi.org/10.1097/CJI.0000000000000044

Ejemplares similares